Trials / Completed
CompletedNCT05847088
Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema:
Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema: Anatomical and Functional Outcomes of Treatment and Retreatment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 58 (actual)
- Sponsor
- Dar El Oyoun Hospital · Academic / Other
- Sex
- All
- Age
- 16 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
We have been using DEX for refractory DME for a long time (since 2016). Thus, we are sharing our results , evaluating both anatomical and functional outcomes of DEX therapy for refractory DME.
Detailed description
Our study aims at evaluating both anatomical and functional outcomes of DEX therapy for cases of refractory DME, with both a single injection, and /or with retreatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravitreal Dexamethasone Implant for refractory Diabetic macular edema: | Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME. |
Timeline
- Start date
- 2023-02-15
- Primary completion
- 2023-03-28
- Completion
- 2023-04-04
- First posted
- 2023-05-06
- Last updated
- 2023-05-06
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05847088. Inclusion in this directory is not an endorsement.